An integrated in silico and in vitro approach for the identification of potent novel PAD4 inhibitors

In the body's immune system, a specific type of white blood cell called a neutrophil acts as a rapid-response team, rushing to sites of infection or injury to neutralize threats. When these cells encounter a serious problem, they can perform a dramatic self-sacrifice known as NETosis. During this process, the neutrophil unravels its own DNA and mixes it with toxic enzymes, shooting out a sticky, web-like trap to catch and kill invading microbes. This mechanism is vital for survival, but when it goes into overdrive, the same webs that kill bacteria can also damage the body's own tissues. This excessive release of cellular debris is linked to a wide range of serious conditions, including severe inflammation, autoimmune disorders, and organ failure. The chemical switch that triggers this unraveling is an enzyme called PAD4, which acts like a molecular cutter, modifying proteins to loosen the tight coils of DNA inside the cell. If scientists could find a way to turn off this specific switch, they might be able to stop the harmful webs from forming in the first place, potentially treating diseases where inflammation spirals out of control.

Researchers have now taken a significant step toward finding such a solution by combining the power of modern computer modeling with traditional laboratory testing. Instead of testing millions of chemicals one by one, which is slow and expensive, the team used artificial intelligence to sift through a massive digital library of nearly half a million potential drug candidates. They focused their search on a specific pocket of the PAD4 enzyme that had been overlooked by previous drug hunters, looking for molecules that could fit snugly into this space and block the enzyme's activity. The computer models, guided by machine learning algorithms, predicted which molecules would bind most tightly to the target. From this vast digital pool, the system narrowed the field down to just twenty-five promising candidates, which were then physically tested in the lab.

The results of this screening were striking. Two of the selected compounds, labeled 16 and 24, proved to be exceptionally effective at stopping the PAD4 enzyme. In laboratory tests using cell-free systems, these new molecules were far more potent than the current standard treatment, a drug known as Cl-amidine. While the standard drug required a concentration of roughly 6.45 micromolar to achieve a certain level of inhibition, compound 16 achieved a similar or better effect at just 0.81 micromolar, and compound 24 worked at 3.07 micromolar. This means the new compounds are significantly stronger, requiring much smaller amounts to do the same job. Crucially, the researchers also checked to see if these powerful inhibitors were safe for the cells they were meant to protect. They found that even at high concentrations up to 100 micromolar, the new compounds did not kill the human cells used in the experiments, whereas the standard drug began to show toxicity at much lower levels. This suggests that the new molecules have a much wider safety margin, a critical factor for any potential future medicine.

When the team moved on to test how these compounds affected the actual process of NETosis, the findings continued to support their potential. They used human cells that had been trained to behave like neutrophils and stimulated them to release their DNA webs. In the untreated cells, the webs formed freely, glowing brightly under a microscope as they trapped the surrounding environment. However, when the cells were pre-treated with compounds 16 and 24, the formation of these webs was dramatically reduced. The cells retained their structural integrity, and the release of toxic enzymes and DNA fragments was suppressed. The researchers confirmed this by measuring the levels of specific markers associated with the process, such as citrullinated histones and neutrophil elastase, all of which were significantly lower in the treated cells. This confirmed that the compounds were successfully stopping the chemical cascade that leads to the destructive release of cellular contents.

The study did not stop at the neutrophils; it also explored the ripple effects of this inhibition on other immune cells. Neutrophils that have released their webs can travel to nearby tissues and trigger a second wave of inflammation by activating macrophages, another type of immune cell. These macrophages, when exposed to the webs, often become overactive, releasing their own inflammatory signals and producing harmful levels of oxidative stress. The researchers isolated the webs from neutrophils that had been treated with the new compounds and introduced them to macrophages. They found that the macrophages exposed to these "tamed" webs remained calm. They did not show the signs of stress or activation seen in cells exposed to untreated webs. Specifically, the levels of reactive oxygen species and the expression of inflammatory markers were kept low, indicating that by stopping the neutrophils from releasing their webs, the new compounds also prevented the subsequent inflammatory damage to surrounding tissues.

This work demonstrates a clear path from computer simulation to biological reality, identifying two novel molecules that can effectively block the PAD4 enzyme without harming the cells. By targeting a specific, less-explored region of the enzyme, the researchers found compounds that are not only more potent than existing treatments but also safer for the cells they interact with. The study confirms that inhibiting PAD4 can break the cycle of inflammation, stopping both the initial release of neutrophil webs and the secondary inflammatory response in macrophages. While these findings are currently limited to laboratory settings, they provide a strong foundation for developing new therapies that could one day help patients suffering from conditions driven by excessive inflammation and tissue damage. The next steps will involve testing these compounds in complex living systems to see if they can translate these laboratory successes into real-world medical treatments.